Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Michael Davis

Showing results (371-380 of 391) with videos related to

Pageof 40
Sort By:
Cancer Epidemiology, Biomarkers & Prevention : a Publication of the American Association for Cancer Research, Cosponsored by the American Society of Preventive Oncology|August 27, 2009
Association of folate-pathway gene polymorphisms with the risk of prostate cancer: a population-based nested case-control study, systematic review, and meta-analysisSimon M Collin, Chris Metcalfe, Luisa Zuccolo, et al.
British Journal of Cancer|July 17, 2020
The ProtecT randomised trial cost-effectiveness analysis comparing active monitoring, surgery, or radiotherapy for prostate cancerSian M Noble, Kirsty Garfield, J Athene Lane, et al.
JCI Insight|April 20, 2018
Neutrophil subsets and their gene signature associate with vascular inflammation and coronary atherosclerosis in lupusPhilip M Carlucci, Monica M Purmalek, Amit K Dey, et al.
Annals of the Rheumatic Diseases|August 1, 2022
Peroxisome proliferator activated receptor-γ agonist pioglitazone improves vascular and metabolic dysfunction in systemic lupus erythematosusSarfaraz Hasni, Yenealem Temesgen-Oyelakin, Michael Davis, et al.
European Urology|July 7, 2020
Erratum to 'Ten-year Mortality, Disease Progression, and Treatment-related Side Effects in Men with Localised Prostate Cancer from the ProtecT Randomised Controlled Trial According to Treatment Received' [European Urology 77 (2020) 320-330]David E Neal, Chris Metcalfe, Jenny L Donovan, et al.
European Urology|October 11, 2016
Mortality Among Men with Advanced Prostate Cancer Excluded from the ProtecT TrialThomas J Johnston, Greg L Shaw, Alastair D Lamb, et al.
European Urology|November 28, 2019
Ten-year Mortality, Disease Progression, and Treatment-related Side Effects in Men with Localised Prostate Cancer from the ProtecT Randomised Controlled Trial According to Treatment ReceivedDavid E Neal, Chris Metcalfe, Jenny L Donovan, et al.
BJU International|April 4, 2022
Functional and quality of life outcomes of localised prostate cancer treatments (Prostate Testing for Cancer and Treatment [ProtecT] study)Janet Athene Lane, Jenny L Donovan, Grace J Young, et al.
The New England Journal of Medicine|March 13, 2023
Fifteen-Year Outcomes after Monitoring, Surgery, or Radiotherapy for Prostate CancerFreddie C Hamdy, Jenny L Donovan, J Athene Lane, et al.
Health Technology Assessment (Winchester, England)|August 11, 2020
Active monitoring, radical prostatectomy and radical radiotherapy in PSA-detected clinically localised prostate cancer: the ProtecT three-arm RCTFreddie C Hamdy, Jenny L Donovan, J Athene Lane, et al.
Pageof 40

Showing results (371-380 of 391) with videos related to

Sort By:
Pageof 40
Cancer Epidemiology, Biomarkers & Prevention : a Publication of the American Association for Cancer Research, Cosponsored by the American Society of Preventive Oncology|August 27, 2009
Association of folate-pathway gene polymorphisms with the risk of prostate cancer: a population-based nested case-control study, systematic review, and meta-analysisSimon M Collin, Chris Metcalfe, Luisa Zuccolo, et al.
British Journal of Cancer|July 17, 2020
The ProtecT randomised trial cost-effectiveness analysis comparing active monitoring, surgery, or radiotherapy for prostate cancerSian M Noble, Kirsty Garfield, J Athene Lane, et al.
JCI Insight|April 20, 2018
Neutrophil subsets and their gene signature associate with vascular inflammation and coronary atherosclerosis in lupusPhilip M Carlucci, Monica M Purmalek, Amit K Dey, et al.
Annals of the Rheumatic Diseases|August 1, 2022
Peroxisome proliferator activated receptor-γ agonist pioglitazone improves vascular and metabolic dysfunction in systemic lupus erythematosusSarfaraz Hasni, Yenealem Temesgen-Oyelakin, Michael Davis, et al.
European Urology|July 7, 2020
Erratum to 'Ten-year Mortality, Disease Progression, and Treatment-related Side Effects in Men with Localised Prostate Cancer from the ProtecT Randomised Controlled Trial According to Treatment Received' [European Urology 77 (2020) 320-330]David E Neal, Chris Metcalfe, Jenny L Donovan, et al.
European Urology|October 11, 2016
Mortality Among Men with Advanced Prostate Cancer Excluded from the ProtecT TrialThomas J Johnston, Greg L Shaw, Alastair D Lamb, et al.
European Urology|November 28, 2019
Ten-year Mortality, Disease Progression, and Treatment-related Side Effects in Men with Localised Prostate Cancer from the ProtecT Randomised Controlled Trial According to Treatment ReceivedDavid E Neal, Chris Metcalfe, Jenny L Donovan, et al.
BJU International|April 4, 2022
Functional and quality of life outcomes of localised prostate cancer treatments (Prostate Testing for Cancer and Treatment [ProtecT] study)Janet Athene Lane, Jenny L Donovan, Grace J Young, et al.
The New England Journal of Medicine|March 13, 2023
Fifteen-Year Outcomes after Monitoring, Surgery, or Radiotherapy for Prostate CancerFreddie C Hamdy, Jenny L Donovan, J Athene Lane, et al.
Health Technology Assessment (Winchester, England)|August 11, 2020
Active monitoring, radical prostatectomy and radical radiotherapy in PSA-detected clinically localised prostate cancer: the ProtecT three-arm RCTFreddie C Hamdy, Jenny L Donovan, J Athene Lane, et al.
Pageof 40